Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

BACKGROUND Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS We evaluated 6341 (2111 TNBC and 4230 non-TNBC) breast cancer samples at a central laboratory for biomarkers of potential drug response across multiple platforms, including gene sequencing, protein expression, and gene copy number. RESULTS TNBC expresses androgen receptor (AR) in a significantly (P < .05) lower percentage of cases (17%) than hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-positive breast carcinomas (59% and 79%, respectively), and gene comutations were differentially associated with AR-positive versus AR-negative cases. Higher AR expression levels in TNBC predicted for lower Ki-67 levels. Seventy percent of TNBC harbored a phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), v-akt murine thymoma viral oncogene homolog 1 (AKT1), or phosophatase and tensin homolog (PTEN) aberration. TNBC patients had a significantly lower PIK3CA mutation rate (13%) than all other subtypes (P < .05) and a higher tumor protein p53 (TP53) mutation rate (64%) than the estrogen receptor (ER)-positive cases (approximately 30%; P < .05). Topoisomerase 2 (TOP2A) amplification was observed in 1.3% of TNBC and in 1.6% of HER2-negative, HR-positive cancers; in contrast, HER2-positive, HR-negative or HR-positive cancers exhibited TOP2A amplification in 19% and 40% of cases, respectively (P <.05). CONCLUSION Multi-platform molecular profiling identifies subgroups of TNBC with different biomarker profiles, suggesting numerous potentially targetable alterations in TNBC. TNBC is further characterized by different gene mutations and proliferative activity relative to AR expression, highlighting a need for comprehensive pathologic examination with potential to develop different, individualized treatment options.

[1]  J. Barrett,et al.  PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer , 2010, Clinical Cancer Research.

[2]  Takashi Suzuki,et al.  Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer. , 2013, Human pathology.

[3]  Aleix Prat Aparicio.  Comprehensive molecular portraits of human breast tumours , 2012 .

[4]  Carlos L Arteaga,et al.  Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. , 2012, Critical reviews in oncogenesis.

[5]  Francisco M. De La Vega,et al.  Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities , 2012, Molecular Cancer Therapeutics.

[6]  R. Yelensky,et al.  Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms , 2014, Oncotarget.

[7]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[8]  C. Sotiriou,et al.  Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer , 2013, Journal of the National Cancer Institute.

[9]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[10]  S. Millis,et al.  Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. , 2015, Clinical genitourinary cancer.

[11]  G. Mills,et al.  Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer , 2011, Clinical Cancer Research.

[12]  P. Tan,et al.  Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy , 2011, Breast Cancer Research.

[13]  Meenakshi Singh,et al.  Triple-negative breast carcinoma: current and emerging concepts. , 2014, American journal of clinical pathology.

[14]  W. Gerald,et al.  Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer , 2009, Clinical Cancer Research.

[15]  M. Ebert,et al.  Her2/neu testing in gastric cancer: evaluating the risk of sampling errors , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  B. Vojtesek,et al.  Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. , 2014, Oncology reports.

[17]  P. Bedard,et al.  Clinical application of high-throughput genomic technologies for treatment selection in breast cancer , 2013, Breast Cancer Research.

[18]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Y. Mao,et al.  The Impact of Androgen Receptor Expression on Breast Cancer Survival: A Retrospective Study and Meta-Analysis , 2013, PloS one.

[20]  W. Park,et al.  Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas , 2006, Clinical Cancer Research.

[21]  Andres Forero,et al.  Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer , 2013, Clinical Cancer Research.

[22]  Raphaël Porcher,et al.  Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15 , 2013, Breast Cancer Research.

[23]  Takashi Suzuki,et al.  Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation , 2013, Cancer science.

[24]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[25]  J. Reis-Filho,et al.  Tackling the Diversity of Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.

[26]  J. Montero,et al.  Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling , 2014, BMC Cancer.

[27]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[28]  W. Park,et al.  ERBB2 kinase domain mutation in the lung squamous cell carcinoma. , 2006, Cancer letters.

[29]  A. Iafrate,et al.  Apocrine-Eccrine Carcinomas: Molecular and Immunohistochemical Analyses , 2012, PloS one.

[30]  G. Sauter,et al.  Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer , 2012, Breast Cancer Research and Treatment.

[31]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[32]  R. Yelensky,et al.  Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. , 2014, Cancer discovery.

[33]  J. Stenvang,et al.  A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer , 2013, Breast Cancer Research and Treatment.

[34]  Puay Hoon Tan,et al.  Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer , 2014, Modern Pathology.

[35]  Ashraf Khan,et al.  Theranostic and molecular classification of breast cancer. , 2014, Archives of pathology & laboratory medicine.

[36]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[37]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[38]  Yuan Qi,et al.  Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers , 2012, Breast Cancer Research and Treatment.

[39]  Gordon B Mills,et al.  PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors , 2014, Breast Cancer Research.

[40]  I. Tannock,et al.  Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[41]  Stephen T. C. Wong,et al.  Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.